TCGA-BL-A13J-01A-11R-A10U-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 2.660972405
- os_event
- true
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HYPOXIA+0.420
- PROTEIN_SECRETION+0.380
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
- CHOLESTEROL_HOMEOSTASIS+0.330
- ANGIOGENESIS+0.310
- UV_RESPONSE_DN+0.290
- MITOTIC_SPINDLE+0.260
- UNFOLDED_PROTEIN_RESPONSE+0.250
- GLYCOLYSIS+0.240
- BILE_ACID_METABOLISM+0.220
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.540
- MYC_TARGETS_V2-0.470
- OXIDATIVE_PHOSPHORYLATION-0.390
- INTERFERON_GAMMA_RESPONSE-0.320
- ALLOGRAFT_REJECTION-0.290
- DNA_REPAIR-0.270
- IL6_JAK_STAT3_SIGNALING-0.220
- XENOBIOTIC_METABOLISM-0.220
- PANCREAS_BETA_CELLS-0.200
- MYC_TARGETS_V1-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BL-A13J-01A-11R-A277-07 | — | — | 0.794 |
| 2 | de751aae-bc7a-4d70-9d06-4417be4facae | — | — | 0.790 |
| 3 | SRR15069611 | — | — | 0.772 |
| 4 | 5b6bd2fd-de8e-4d58-9b38-c3b2bf2ed418 | — | — | 0.750 |
| 5 | 2e6550a8-fbe0-4b31-bb3a-4d7e93709126 | — | — | 0.745 |
| 6 | TCGA-73-4668-01A-01R-1206-07 | — | cohortA1 | 0.733 |
| 7 | a7bda5b9-9c95-4f90-bab6-10ab15ee2b48 | — | — | 0.730 |
| 8 | TCGA-B6-A0RI-01A-11R-A056-07 | — | B | 0.729 |
| 9 | TCGA-BH-A0W4-01A-11R-A109-07 | — | A | 0.728 |
| 10 | TCGA-CV-7416-01A-11R-2081-07 | — | — | 0.725 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HYPOXIA | 0.420 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.380 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.350 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.330 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.310 | Remibrutinib | — uncovered |
| UV_RESPONSE_DN | 0.290 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.260 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.250 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.240 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.220 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.200 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.190 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.180 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.160 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.110 | Inavolisib | — uncovered |